European Medicines Agency to investigate link between Ozempic and rare eye disorder The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns that it may increase the risk of a rare eye condition, the Amsterdam-based agency announced on Friday
Missiroli, S
McGill et al., Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment, Diabetes Care, vol
En www.goutogo.mx, te ayudamos a tomar una decisin informada y segura, con acceso a tratamientos profesionales, envo seguros y atencin personalizada
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al
doi: 10.1089/pho.2007.2062